The use of monoclonal antibody (mAb) in routine clinical practice is now well established and has arguably led to some of the most significant improvements in outcome for patients in hematological malignancies as well as in a wide range of other malignancies including breast and bowel cancer (1–3). Although the single agent activity of most mAb has been modest when used in combination with other antitumor therapies, an additive or synergistic effect has been seen with both chemotherapy and radiotherapy (2). The impressive increases in clinical response rates seen with the combination of mAb and combination chemotherapy has led to not only highly impressive increases in response rates, relapse-free survival (RFS) but even overall survival (3).